
Founded in 2021, AccurEdit is dedicated to developing and commercializing safe, effective, and target-specific in vivo gene editing therapies, along with delivery technologies, for the treatment of severe or life-threatening genetic and acquired diseases worldwide. AccurEdit is advancing multiple pipeline products. ART001 (ATTR) and ART002 (PCSK9), its first two leading assets, have entered into human clinical trials and both demonstrate the potential to be the Best-in-Class or First-in-class therapies in respective fields. AccurEdit has established an industry-leading end-to-end technology…
Annual Revenue$50M to $100M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.